肝细胞癌免疫治疗研究进展

Research advances in hepatocellular carcinoma immunotherapy

肝细胞癌(hepatocellular carcinoma,HCC)是人类最常见的恶性肿瘤之一,易复发转移,预后差。近年来,以免疫检查点抑制疗法为代表的免疫治疗已经在HCC病人中显示出强大的抗肿瘤能力,尤其是与酪氨酸激酶抑制剂或放疗等治疗措施联用可显著提升HCC的客观缓解率,临床应用前景良好。同时,包括CAR-T细胞治疗、新抗原疫苗等新一代免疫疗法也在HCC治疗中展现较好的应用前景。

Hepatocellular carcinoma(HCC)is one of the most common malignant tumors in human,which is prone to recurrence metastasis and with poor therapeutil outcomes.Recently,immunotherapies,represented by immune checkpoint inhibitors(ICIs),have demonstrated robust antitumor effects in patients with HCC;particularly,combination therapies of ICIs with tyrosine kinase inhibitors or radiotherapy can significantly improve the objective response rate,showing promise in clinical applications.Meanwhile,the new-generation immunotherapies including CAR-T therapy and neoantigen vaccine also have shown great promise for HCC treatment.